Overview

Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors

Status:
Unknown status

Trial end date:
2020-12-01

Target enrollment:

Participant gender:

Summary

This study is a single-arm,phase II study of gefitinib in patient with epidermal growth factor receptor amplification Refractory solid tumors. Gefitinib 250 mg will be administered orally daily. To investigate the efficacy and safety of gefitinib in patient with epidermal growth factor receptor amplification Refractory solid tumors.

Phase:

Phase 2

Details

Lead Sponsor:

Samsung Medical Center

Treatments:

Gefitinib